Joelma Ines Tagliapietra Barros, Francisco Vagnaldo Fechine, Renan Magalhães Montenegro Júnior, Otoni Cardoso do Vale, Virgínia Oliveira Fernandes, Marcellus Henrique Loiola Ponte de Souza, Gilmara Holanda da Cunha, Manoel Odorico de Moraes, Catarina Brasil d'Alva, Maria Elisabete Amaral de Moraes
{"title":"西格列汀治疗对2型糖尿病患者躯体感觉诱发电位及代谢控制的影响。","authors":"Joelma Ines Tagliapietra Barros, Francisco Vagnaldo Fechine, Renan Magalhães Montenegro Júnior, Otoni Cardoso do Vale, Virgínia Oliveira Fernandes, Marcellus Henrique Loiola Ponte de Souza, Gilmara Holanda da Cunha, Manoel Odorico de Moraes, Catarina Brasil d'Alva, Maria Elisabete Amaral de Moraes","doi":"10.1590/0004-2730000002914","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy.</p><p><strong>Materials and methods: </strong>Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day).</p><p><strong>Results: </strong>There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin.</p><p><strong>Conclusion: </strong>The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.</p>","PeriodicalId":8395,"journal":{"name":"Arquivos brasileiros de endocrinologia e metabologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2014-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1590/0004-2730000002914","citationCount":"2","resultStr":"{\"title\":\"Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.\",\"authors\":\"Joelma Ines Tagliapietra Barros, Francisco Vagnaldo Fechine, Renan Magalhães Montenegro Júnior, Otoni Cardoso do Vale, Virgínia Oliveira Fernandes, Marcellus Henrique Loiola Ponte de Souza, Gilmara Holanda da Cunha, Manoel Odorico de Moraes, Catarina Brasil d'Alva, Maria Elisabete Amaral de Moraes\",\"doi\":\"10.1590/0004-2730000002914\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy.</p><p><strong>Materials and methods: </strong>Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day).</p><p><strong>Results: </strong>There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin.</p><p><strong>Conclusion: </strong>The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.</p>\",\"PeriodicalId\":8395,\"journal\":{\"name\":\"Arquivos brasileiros de endocrinologia e metabologia\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2014-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1590/0004-2730000002914\",\"citationCount\":\"2\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Arquivos brasileiros de endocrinologia e metabologia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1590/0004-2730000002914\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Arquivos brasileiros de endocrinologia e metabologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1590/0004-2730000002914","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Effect of treatment with sitagliptin on somatosensory-evoked potentials and metabolic control in patients with type 2 diabetes mellitus.
Objective: To evaluate the effect of sitagliptin on somatosensory-evoked potentials (SEPs) and metabolic control in patients with type 2 diabetes mellitus without clinical diabetic neuropathy.
Materials and methods: Interventional, prospective, and open study. Patients with less than six months from the diagnosis were included. Examinations of SEPs and laboratory tests at fasting and after food stimulation were performed before and after three months of treatment with sitagliptin (100 mg/day).
Results: There was a reduction in the mean levels of HbA1c (P < 0.0001), fasting glucose (P = 0.001), total cholesterol (P = 0.019), and ALT (P = 0.022). An increase in active GLP-1 was found at the end of the study (P = 0.0025). Several SEPs showed statistically significant differences when analyzed before and after treatment with sitagliptin.
Conclusion: The results give a glimpse of the possible use of sitagliptin in the treatment of some neurodegenerative conditions of the peripheral nervous system, in addition to its already established role in glycemic control.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
